抗p21ras单克隆抗体在甲状腺乳头状癌中的免疫反应性研究

目的评价抗p21ras单克隆抗体（mAb）KGH-R1、KGH-R2、KGH-R3与原发性甲状腺乳头状癌及相应正常组织的免疫反应性,为该抗体的临床应用奠定基础。方法用本实验室制备的广谱抗p21ras mAb KGH-R1、KGH-R2、KGH-R3抗体,对30例甲状腺乳头状癌和30例周围正常甲状腺组织进行免疫组化染色,计算各样本的阳性细胞百分比和组织学评分（HSCORE）分值,确定这三种抗体对甲状腺乳头状癌及甲状腺正常组织免疫反应性的差异。结果抗p21ras单克隆抗体KGH-R1、KGH-R2、KGH-R3分别与70.00%（21/30）、76.67%（23/30）、60.00%（18/30）的甲状腺乳头状癌发生免疫反应,阳性样本的平均阳性细胞百分比分别为为81%、100%、68%,平均HSCORE评分分别为277.50分、272.50分、264.00分;分别与30.00%（9/30）、23.33%（7/30）、33.33%（10/30）的正常甲状腺组织发生免疫反应,阳性样本的平均阳性细胞百分比分别为7.75%、8.00%、10.20%,平均HSCORE评分分别为7.75分、8.00分、10.20分。结论这三种单克隆抗体在甲状腺乳头状癌中免疫反应性较强,而在正常甲状腺组织的免疫反应性较弱或呈阴性反应。因此,这三种单克隆抗体可进一步开发为治疗性抗体,用于原发性甲状腺乳头状癌的临床治疗。

Research on immunoreactivity of anti-p21ras monoclonal antibodies to thyroid papillary carcinoma

Objective To evaluate the immunoreactivity of anti-p21ras monoclonal antibodies namely KGH-R1,KGH-R2 and KGH-R3 to primary thyroid papillary carcinoma and the corresponding normal tissues,and to establish basis for the clinical application of these antibodies.Methods Immunohistochemical staining was performed in samples from 30 cases of thyroid papillary carcinoma and 30 cases of normal thyroid tissues using self-prepared broad-spectrum anti-p21ras monoclonal antibodies i.e.KGH-R1,KGH-R2 and KGH-R3.Percentages of positive cells and histological scores(HSCORE)in these samples were calculated.Differences of the immunoreactivity of the three antibodies to thyroid papillary carcinoma and the normal thyroid tissues were determined.Results Immunoreaction of KGH-R1,KGH-R2 and KGH-R3 was respectively found in 70.00%(21/30),76.67%(23/30)and 60.00%(18/30)of the thyroid papillary carcinoma.The average percentages of positive cells were respectively 81%,100% and 68% in positive samples.The average HSCORE was 277.50,272.50 and 264.00,respectively.Immunoreaction of these antibodies was found in 30.00%(9/30),23.33%(7/30)and 33.33%(10/30)of normal thyroid tissues,in which the average percentages of positive cells were 7.75%,8.00% and 10.20% and the average HSCORE was 7.75,8.00 and 10.20,respectively.Conclusion The immunoreactivity of KGH-R1,KGH-R2 and KGH-R3 is stronger in thyroid papillary carcinoma than that in the corresponding normal tissues,which indicates that these antibodies may be potential therapeutic antibodies for primary thyroid papillary carcinoma.